This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics are included in this Analyst Blog.
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
by Zacks Equity Research
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
by Kinjel Shah
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.
How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study
by Kinjel Shah
The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?
by Kinjel Shah
Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study
by Zacks Equity Research
LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
by Kinjel Shah
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Why Momentum Stocks & ETFs Are Crushing the Market
by Neena Mishra
The momentum factor has been a standout performer this year, but which ETF should you buy?
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
by Zacks Equity Research
J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients
Why Is Lilly (LLY) Down 5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
by Zacks Equity Research
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
AMGN Stock Down Despite Strong Data From Obesity Drug Study
by Zacks Equity Research
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
by Kinjel Shah
The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
by Zacks Equity Research
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
by Zacks Equity Research
Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
by Zacks Equity Research
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
by Kinjel Shah
EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.
Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
by Sundeep Ganoria
The plunge in Viking Therapeutics' share price can be attributed to the rising competition in the sector to secure a position in the booming obesity market.
J&J Loses Around $24B in a Month: How to Play the Stock?
by Kinjel Shah
The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley
by Zacks Equity Research
Eli Lilly, PepsiCo and Morgan Stanley are included in this Analyst Blog.